糖尿病視網(wǎng)膜病變是一種常見(jiàn)的糖尿病微血管病變和神經(jīng)退行性病變，可造成視網(wǎng)膜細(xì)胞不可逆損傷，造成患者視力下降。目前臨床治療糖尿病視網(wǎng)膜病尚缺乏根治的治療手段，且常規(guī)治療藥物也較缺乏。人參皂苷Rg₁為人參中重要活性成分，具有多種活性，可通過(guò)減輕炎癥反應(yīng)，減輕氧化應(yīng)激反應(yīng)，抑制視網(wǎng)膜細(xì)胞凋亡，抑制血管形成，延緩視網(wǎng)膜纖維化，預(yù)防突觸神經(jīng)變性以改善糖尿病視網(wǎng)膜病變。總結(jié)了人參皂苷Rg₁改善糖尿病視網(wǎng)膜病變的藥理作用研究進(jìn)展，為人參皂苷Rg₁的臨床使用提供參考。

Diabetes retinopathy is a common microvascular disease and neurodegenerative disease in diabetes, which can cause irreversible damage to retinal cells and cause visual impairment in patients. At present, the clinical treatment of diabetes retinopathy is still lack of a radical cure method, and lack of conventional treatment drugs. Ginsenoside Rg₁ is an important active ingredient in Ginseng Radix et Rhizoma, with various activities. Ginsenoside Rg₁ can improve diabetic retinopathy by reducing inflammation, alleviating oxidative stress, inhibiting retinal cell apoptosis, suppressing angiogenesis, delaying retinal fibrosis, and preventing synaptic degeneration. This article summarized the research progress of pharmacological effects of ginsenoside Rg₁ on diabetes retinopathy, providing reference for clinical use of ginsenoside Rg₁.

R977